Vaccine strategies for infectious diseases

Bibliography

• DE QUADROS CA, ANDRUS JK, OLIVE JM et al: Eradica-tion of poliomyelits . Progress for the Americas. Ped. Inf. Dis. (1991) 10:222–229.
   PubMed Web of Science ®Google Scholar
• FOLKERS GK, FAUCI AS: The role of US Governmentagencies in vaccine research and development. Nature Med. Vaccine suppl. (1998) 4,5:491–494.
   PubMed Web of Science ®Google Scholar
• MURRAY CJL, LOPES A: The Global Burden of Disease and Injury. Harvard University (1996) 1.
   Google Scholar
• Two cheers for the multilateral malaria initiative [edi-torial]. Nature (1997) 338:221.
   Google Scholar
• HAYNES BF, PANTALEO G, FAUCI AS: Toward an under-standing of the correlates of protective immunity to HIV infection. Science (1996) 271:324–328.
   PubMed Web of Science ®Google Scholar
• RUSSEL PK, HAWNSON CP: Vaccine against malaria: hope in a gathering storm. National Academy Press, Washington DC (1996).
   Google Scholar
• STONTETE JA, SLAONI M, HEPPNER DG et al.: A prelimi-nary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum ma-laria. N Engl. J Med. (1997) 336:86–91.
   PubMed Web of Science ®Google Scholar
• FOULDS J: The Comstock conference on Tubercolosis vaccines. ASM News (1997) 63:256–258.
   Google Scholar
• SHEARER GM, CLERICI M: Vaccine strategies: selective elicitation of cellular or humoral immunity? Trend Bio-tech. (1997) 15:106–109.
   Google Scholar
• LIEW FY, PARISH CR: Regulation of the immune re-sponse by antibody. I. Suppression of antibody forma-tion and concomitant enhancement of cell-mediated immunity by passive antibody. Cell. Immunol (1972) 4:66–85.
   Google Scholar
• CLERICI M, CLARK EA, POLACINO P et al.: T-cell prolifera-tion to subinfectious SW correlates with lack of infec-tion after challenge of macaques. AIDS (1995) 8:1391–1395.
   Web of Science ®Google Scholar
• BRETSCHER PA: A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immu-nol. Today (1992) 13:342–345.
   PubMedGoogle Scholar
• BRETSCHER PA: Prospects for low dose BCG vaccina-tion against tuberculosis. Immunobiology (1994) 4:548–554.
   Google Scholar
• THOMPSON CB: Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell (1995) 81:979–982.
   PubMed Web of Science ®Google Scholar
• CLERICI M, DE PALMA L, ROILIDES E et al.: Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J. Clin. Invest. (1993) 91:2829–2836.
   PubMed Web of Science ®Google Scholar
• UN MA: Vaccine developments. Nature Med. Vaccine suppl. (1998) 4,5:515–519.
   PubMed Web of Science ®Google Scholar
• CHATTERGOON M, BOYER J, WEINER DB: Genetic im-munization: a new era in vaccines and immune thera-peutics. FASEB J (1997) 11:753–763.
   PubMed Web of Science ®Google Scholar
• KATZ SL: Future vaccines and a global perspective. Lan-cet (1997) 350:1767–1770.
   PubMed Web of Science ®Google Scholar
• MAZZOLI SD, TRABATTONI S, CAPUTO LO et al: HIV-specific mucos al and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Med. (1997)3:1250–1257.
   PubMed Web of Science ®Google Scholar
• BLOOM BR, WIDDUS R: Vaccine visions and their globalimpact. Nature Med. Vaccine suppl. (1998) 4,5:480–484.
   PubMed Web of Science ®Google Scholar
• LEVY JA: HIV pathogenesis and long-term survival.AIDS (1993) 7:1401–1418.
   PubMed Web of Science ®Google Scholar
• ROWLAND-JONES SL, MCMICHAEL A: Immune re-sponses in HIV-exposed seronegative : how they re-pelled the virus?. Current Opinion Immunol. (1995) 7:448–455.
   PubMed Web of Science ®Google Scholar
• SHEARER GM, CLERICI M: Protective immunity against HIV : has nature done the experiment for us? Immunol Today (1996) 17:21–24.
   PubMedGoogle Scholar
• ROWLAND JONES SL, NIXON DF, ALDH1OUS MC et al.: HIV specific cytotoxic T cell activity in an HIV exposed but uninfected infant. Lancet (1997) 341:860–861.
   Google Scholar
• CHEYNIER R, LANGLADE-DEMOYEN P, MORESCOT MR et Cytotoxic T lymphocyte response in peripheral blood of children born to HIV-infected mothers. Eur. J; Immunol (1994) 22:2211–2217.
   Web of Science ®Google Scholar
• CLERICI M, LEVIN JM, KESSLER HA et al.: HIV-specific T helper activity in HIV seronegative health care work-ers accidentally exposed to HIV-contaminated blood. JAMA (1994) 271:42–46.
   PubMed Web of Science ®Google Scholar
• PINTO L: ENV-specific T lymphocyte responses in HIV seronegative health care workers occupationally ex-posed to HIV-contaminated body fluids. J. Clin. Invest. (1995) 96:867–876.
   PubMed Web of Science ®Google Scholar
• ROWLAND JONES SL, NIXON DF, ALDHOUS MC et al: HIVspecific cytotoxyc T cells in HIV-exposed but unin-fected Gambian women. Nature Med (1995) 1:59–64.
   PubMed Web of Science ®Google Scholar
• FOWKE KR, NAGELKERKE NJ, KIMANI J et al: Resistanceto HIV infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet (1996) 348:1347–1351.
   PubMed Web of Science ®Google Scholar
• LANGLADE-DEMOYEN P, NGO-GIANG-HNONG F, FER-CHAL F, OKSENHENDLER E: HIV-neg-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV infected patients. J. Clin. Invest. (1994) 93:1297–1307.
   Google Scholar
• DESROSIERS RC: Non-human primate models for AIDS vaccines. AIDS (1995) 9 (suppl. A):5137–5141.
   Google Scholar
• BURTON DR: A Vaccine for HIV type-1: the antibody perspective. Proc. Natl. Acad. Sci. USA (1997) 94:10018–10023.
   PubMed Web of Science ®Google Scholar
• MOORE JP, HO DD: HIV-1 neutralization: the conse-quence of viral adaptation to growth on transformed T cells. AIDS (1995) 9 (suppl. A):S117–S136.
   Google Scholar
• MONTEFIORI DC, PANTALEO G, FINK LM eta].: Neutraliz-ing and infectio-enhancing antibody responses to hu-man immunodeficiency virus Type 1 in long-term non progressors. J. Infect. Dis. (1996) 173(0:60–67.
   Google Scholar
• MOOG C, FLEURY HJ, PELLEGRIN I, KIM A, AUBERTIN AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus Type 1 infected individuals. J. Virol (1997) 71 (5):3734–3741
   PubMed Web of Science ®Google Scholar
• PILGRIM AK, PANTALEO G, COHEM OJ et al. Neutralizing antibody responses to human immunodeficiency virus Type 1 in primary infection and long-term nonprogressive infection. J. Infect. Dis. (1997) 176(4)924–939.
   Google Scholar
• PELLEGRIN I, LEGRAND E, NEAU D et al.: Kinetics of ap-pearance of neutralizing antibody in 12 patients with primary or recent 111V-1 infection and relationship with plasma and cellular viral load. J. AIDS and Human Retrov. (1996) 11(5):438–47.
   PubMedGoogle Scholar
• KOUP RA, SAFRIT JT, CAO Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus Type 1 syndrome. J. Vim]. (1994) 68(7):4650–4655.
   Web of Science ®Google Scholar
• WALKER CM, MOODY DJ, STITES DP, LEVY JA: CD8+ lym-phocytes can control HIV infection in vitro by sup-pressing virus replication. Science (1986) 234:1563–1566.
   PubMed Web of Science ®Google Scholar
• TSUBOTA H, LORD CI, WATKINS DI, MORIMOTO C, LET-VIN NL: A cytotoxic T lymphocyte inhibits acquired hu-man immunodeficiency virus Type 1 replication in peripheral blood lymphocytes. J. Exp. Med. (1989) 169 (4):1421–1434.
   PubMed Web of Science ®Google Scholar
• CLERICI M, SISON AV, BERZOFSKY JA et al.: Cellular im-mune factors associated with mother -to-infant trans-mission of HIV. AIDS (1993) 7:1427–1433.
   PubMed Web of Science ®Google Scholar
• DE MARIA A, CIRILLO C, MORETTA L: Occurrence of 111V-1 specific cytolityc T cell activity in apparently un-infected children born to 111V-1 infected mothers. J. In-fect. Dis. (1994) 170:1296–1299.
   PubMed Web of Science ®Google Scholar
• PANTALEO G, DEMAEST JF, SOUDEYNS H et al.: Major ex-pansion of CD8+ T cell with a predominant V beta us-age during the primary immune response to HIV. Nature (1994) 370:463–467.
   PubMed Web of Science ®Google Scholar
• CHEN ZW, KOU ZC, LEKUTIS C et al: T cell receptor V beta repertoire in an acute infection of rhesus mon-keys with simian immunodeficiency viruses and a chi-meric simian-human immunodeficiency virus. J. Exp. Med. (1995) 182(0:21–31.
   PubMedGoogle Scholar
• MUSEY L, HUGHES J, SCHACKER T eta].: Cytotoxic T cell responses, viral load, and disease progression in early human immunodeficiency virus Type 1 infection. New Engl. J. Med (1997) 337(18):1267–1274.
   Google Scholar
• OGG GS, JIN X, BONHOEFFER S et al.: Quantitation of 111V-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 279:2103–2106.
   PubMed Web of Science ®Google Scholar
• LETVIN LN: Progress in the development of an HIV vac-cine. Science (1998) 280:1875–1880.
   PubMed Web of Science ®Google Scholar
• DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL PK, DES-ROSIERS RC: Protective effects of a live attenuated SW vaccine with a deletion in the nef gene. Science (1992) 258:1938–1941.
   PubMed Web of Science ®Google Scholar
• WHATMORE AM, COOK N, HALL GA et al: Repair and evolution of nef in vivo modulates simian immunode-ficiency virus virulence. J. Vim]. (1995) 69 (8)5117–5123.
   Google Scholar
• BABA TW, JEONG YS, PENNICK D et al.: Pathogenicity of live, attenuated SW after mucosal infection of neonatal macaques. Science (1995) 267:1820–1825.
   PubMed Web of Science ®Google Scholar
• DEACON NJ, TSYKIN A, SOLOMON A et al. Genomic structure of an attenuated quasi species of 111V-1 fromblood transfusion donor and recipients. Science (1995) 230:988–991.
   Google Scholar
• MURPHEY-CORB M, MARTIN LN, DAVISON-FAIRBURN B eta].: A formalin-inactivated whole SW vaccine confers protection in macaques. Science (1989) 246:1293–1297.
   Google Scholar
• STOTT EJ: Anti-cell antibody in macaques. Nature (1991) 353:393.
   PubMed Web of Science ®Google Scholar
• CLERICI M, PINTO LA, SHEARER GM: Alloimmunizationas a possible strategy for immune-based therapy and vaccine design against 'IN-AIDS. Immunol. Today (1999) (In press).
   Google Scholar
• BERMAN PW, GROOPMAN JE, GREGORY T: Human im-munodeficiency virus Type 1 challenge of chimpan-zees immunized with recombinant envelope glyprotein gp120. Proc. Natl. Acad. Sci. USA (1997) 85(14)5200–5204.
   Google Scholar
• MASCOLA JR, SNYDER SW, WILSOW OS et al.: Immuniza-tion with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary insolated of human immunodefi-ciency virus Type 1. J. Infect. Dis. (1996) 173:340–348.
   PubMed Web of Science ®Google Scholar
• LETVIN NL, MONTEFIORI DC, YASUTOMI Y et al.: Potent,protective anti-HIV immune responses generated by bimodal HIV-envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA (1997) 94(17):9378–9383.
   PubMed Web of Science ®Google Scholar
• BOYER JD, UGEN KE, WANG B. et al.: Protection of chim-panzees from high-dose heterologous 111V-1 challenge by DNA vaccination. Nature Med. (1997) 3(5):526–532.
   Google Scholar
• MILLER LH, HOFFMAN SL: Research toward vaccinesagainst malaria. Nature Med. Vaccine suppl. (1998) 4,5:520–524.
   PubMed Web of Science ®Google Scholar
• HOFFMAN SL, FRANKE ED, HOLLINGDALE MR, DRUILHEP: Attacking the infected hepatocyte. In: Malarian Vac-cine Development: A Multi-Immune Response Approach, Hoffman SL (Ed.), American Society of Microbiology, Wash-ington DC. (1996):35–75.
   Google Scholar
• DOOLAN DL, HOFFMAN SL, SOUTHWOOD S et al.: De-generate cytotoxic T cell epitopes from Plasmodium falciparum restricted by multiple HLA-A and HLA-B su-pertype alleles. Immunity (1997) 7:97–112.
   PubMed Web of Science ®Google Scholar
• HOFFMAN SL, DOOLAN DL, SEDEGAH M. et al.: Toward clinical trials of DNA vaccines against malaria. Immu-nol Cell Biol. (1997) 75:376–381.
   Google Scholar
• WEISS W eta].: A plasmid encoding murine GMCSF in-creases protection conferred by a malaria DNA vac-cine. J. Immunol (1998) (In press).
   Google Scholar
• SCHNEIDER J, GILBERT SC, BLACHARD TJ et al.: En-hanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccina-tion by boosting with modified vaccinia virus Ankara. Nature Med. (1998) 4:397–402.
   PubMed Web of Science ®Google Scholar
• SEDEGAH M et al.: Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA (1998) (In press).
   Google Scholar
• GILBERT SC, PLEBANSKI M, GUPTA S etal.: Association of malaria parasite population structure, HLA, and im-munological antagonism. Science (1998) 279:1179–1177.
   Google Scholar